| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6958161 | MAYNE PHARMA | Modified release coated drug preparation |
Dec, 2022
(1 year, 4 months ago) | |
| US8715724 | MAYNE PHARMA | Tabletting process |
Feb, 2028
(3 years from now) | |
| US9511031 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(10 years from now) | |
| US9295652 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(10 years from now) | |
| US9446057 | MAYNE PHARMA | Controlled release doxycycline |
Dec, 2034
(10 years from now) | |
Doryx Mpc is owned by Mayne Pharma.
Doryx Mpc contains Doxycycline Hyclate.
Doryx Mpc has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Doryx Mpc are:
- US6958161
Doryx Mpc was authorised for market use on 19 December, 2014.
Doryx Mpc is available in tablet, delayed release;oral dosage forms.
Doryx Mpc can be used as to treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet.
The generics of Doryx Mpc are possible to be released after 23 December, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Apr 11, 2016 |
| New Dosing Schedule(D-136) | Apr 11, 2016 |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 19 December, 2014
Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet
Dosage: TABLET, DELAYED RELEASE;ORAL
DORYX MPC family patents
